Managed Healthcare Executive July 2, 2024
The FDA may approve KarXT, an antipsychotic that does not have the side effects of some other antipsychotics because it does not affect dopamine receptors.
For the drug industry, 2023 turned out to be a banner year for FDA drug approvals with a total of 55. The FDA has approved 21 novel drugs so far this year, including Rezdiffra (resmetirom), the first treatment approved for noncirrhotic nonalcoholic steatohepatitis, and Tryvio (aprocitentan), the first novel antihypertensive in almost 40 years.
Not included in that new drug approval tally are vaccines, such as Moderna’s messenger RNA respiratory syncytial virus vaccine and added indications for drugs that have already passed muster for another use, such as Wegovy’s (semaglutide) new cardiovascular indication.
The second...
Today's Sponsors
Today's Sponsor